There are an estimated 6,000 Mendelian diseases, most of which still lack cures. Gene editing is an essential technology for studies aimed at generating data about disease-causing gene mutations and networks in order to identify optimal therapeutic targets. In this episode, experts will discuss applications of gene editing to improve scientists’ understanding of the relationship between variant and disease in functional genomics studies. They will also talk about the Dharmacon product suite which is designed for CRISPR-based targeted editing in a wide range of cells.
This podcast is the second in a series. Don’t miss episode one Precision Base Editing Meets Single-Cell Multiomics to Advance Cell and Gene Therapies.
Podcast Guests:
Michelle Fraser, PhD
Head of Cell and Gene Therapy
Revvity
Anastasia L. Kaufman, PhD
Senior Scientist, Base Editing R&D,
Cell and Gene Therapy
Revvity
Josh Croteau, PhD
Program Manager, Strategic Partnerships & Commercialization
BioLegend (Revvity)
Produced with support from: